Disease response criteria in Langerhans cell histiocytosis: a global view.

Ilia N Buhtoiarov, Milen Minkov, Reza Vali, Oussama Abla

Abstract readReview

In one paragraph

Review in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Expanding the Toolbox: Utility of HistioTrak for Minimal Residual Monitoring in Pediatric Patients with Langerhans Cell Histiocytosis Treated with Targeted Therapy.Cancers · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ilia N BuhtoiarovDivision of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, R3-118, Cleveland, OH, 44195, USA. buhtoii@ccf.org.ORCID http://orcid.org/0000-0001-5207-4616

Milen MinkovDepartment of Pediatric Hematology/Oncology, University Clinic of Pediatrics, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-6471-8423

Reza ValiDepartment of Diagnostic & Interventional Radiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-2614-9271

Oussama AblaDivision of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-7446-6274

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm with heterogeneous presentations. The discovery of BRAFV600E and other MAPK pathway mutations drastically transformed the treatment landscape, especially for high-risk LCH and CNS-LCH. While treatment strategies for children and adults are somewhat similar, response assessment methodologies remain highly dichotomized.Currently, separate treatment response criteria exist for children and adults, especially in therapeutic trials. Considering the rapid evolution of targeted MAPK-inhibitor therapies, along with ultrasensitive detection of minimal residual disease biomarkers (e.g., circulating BRAFV600E-encoding DNA) and sophisticated imaging tools (18F-FDG-PET and whole-body MRI), harmonization of response criteria in LCH is clearly warranted. The Histiocyte Society Global LCH Treatment Response Harmonization Task Force, a collaborative network of pediatric and adult LCH experts, is set to propose updated pediatric LCH treatment response criteria, which will also serve as the foundation for a universal response assessment tool for pediatric and adult LCH. In this review, we focus on the past, present, and likely future of response assessment in LCH patients, and discuss needs that remain unmet in the targeted therapy era.

Indexed as

Histiocytosis, Langerhans-CellAdultBiomarkersChildHumansProto-Oncogene Proteins B-rafTreatment OutcomeBiomarkersBRAF protein, humanProto-Oncogene Proteins B-rafHarmonizationLangerhans cell histiocytosisResponseTherapy

Identifiers

PMID40287907

DOI10.1007/s12185-025-03989-z

PMCPMC12106586

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.